Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ADC Therapeutics SA Common Shares (NY:ADCT)

1.105 +0.005 (+0.45%)
Streaming Delayed Price Updated: 11:30 AM EDT, Jun 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ADC Therapeutics SA Common Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
A Preview Of ADC Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why ↗
Stephens initiates coverage on ADC Therapeutics (ADCT), highlighting Zynlonta's potential in second-line DLBCL and a promising oncology pipeline. Overweight rating, $6 price target. 
Via Benzinga
News headline image
ADC Therapeutics's Earnings: A Preview ↗
 
Via Benzinga
News headline image
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics to Present at Upcoming Investor Conferences
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADCT Stock Earnings: ADC Therapeutics Beats EPS, Misses Revenue for Q2 2024 ↗
ADCT stock results show that ADC Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
7 Growth Stocks to Buy for Under $5 for Massive Gains ↗
Although growth stocks under $5 are inherently risky and unpredictable, their very nature also facilitates robust upside potential. 
Via InvestorPlace
News headline image
Intapp, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget ↗
Since wealth without health is utterly meaningless, investors may have some confidence with these biotech stocks to buy. 
Via InvestorPlace
News headline image
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADCT Stock Earnings: ADC Therapeutics Beats EPS, Misses Revenue for Q1 2024 ↗
ADCT stock results show that ADC Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
BioNTech Reports Downbeat Earnings, Joins Medical Properties Trust And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
Medifast Reports Mixed Results, Joins Coursera, Chegg And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
From ADC Therapeutics SA
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.